Online Inquiry
Prostate Cancer Growth Modulator
Among the most aggressive and incurable cancers, prostate cancer (PCa) adenocarcinoma is highly prone to bone metastases. Alfa Cytology is committed to providing a comprehensive one-stop modulator development of prostate cancer growth in bone microenvironments, tailored to our clients' requirements against prostate cancer.
Introduction to Modulation of Prostate Cancer Growth in Bone Microenvironments
Many advanced PCa patients develop multiple metastases, usually in the lymph nodes adjacent to the prostate, but also in distant organs. PCa distant metastases are most commonly found in bone, with approximately 70% of patients diagnosed with bone metastases having advanced PCa. The TME surrounding the tumor has been found to have a crucial role in the pathogenesis and progression of PCa in several studies. Tumor cells interact with a complex network of cells and molecules in the TME during prostate cancer primary to metastasis.
Fig.
1 Cellular and molecular interactions of prostate tumor in primary, pre-metastatic and bone metastasis
microenvironment. (Kang, J., et al. 2022)
Genetic Alterations in Bone Metastasis
ETS Family
The ETS family is a class of transcription factors that can regulate the expression of downstream genes by binding to specific sequences on DNA. In prostate cancer, aberrant activation of ETS family genes is associated with enhanced tumor proliferation, migration, and invasion.
TMPRSS2-ERG
In prostate cancer that's spread to the bones, the TMPRSS2-ERG gene fusion can influence disease progression and treatment response. This fusion is a chromosomal change that causes the ERG gene to be over-expressed using TMPRSS2's promoter.
KRas
KRas is an important signaling molecule involved in the regulation of cell growth, differentiation, and survival. KRas mutations are able to induce up-regulation of CD24 expression, which may enhance pluripotency and bone metastasis in prostate cancer.
Bone-targeting Therapy Development for Prostate Cancer
| Name | Phase | Company | Country |
| Zoledronic acid | Market Approval | Novartis | Switzerland |
| Denosumab | Market Approval | Amgen | USA |
Our Services
Alfa Cytology has been deeply involved in the field of modulator development of prostate cancer growth in bone microenvironments for many years, including RANKL/RANK/OPG pathway inhibitor, ETAR inhibitor and Calcium channel blocker development. We have professional knowledge, extensive experience, and cutting-edge technology to escort you through the process of modulator development.
Genetically Engineered
Model
- Large-fragment Gene Editing Model
- Knock-out/Knock-in Model
- Transgenic Model
Mouse Models Simulating Bone Metastasis from Primary PCa
In order to develop effective clinical therapy based on genetic changes, it is crucial to define functional bone metastasis models based on PCa cells' tendency to metastasize to bone.
| Gene | Modification | Phenotype |
| PB-Cre4/PtenL/L/Rb1L/L/Trp53L/L | Conditional triple knockout of Pten, Rb1 and Trp53 | Bone metastasis Small cohort of animals |
| CR2-T-Ag | Conditional activation of T antigen | Bone metastasis |
| Nkx3.1CreERT2/+/PtenL/L/KRasLSL-G12D/+ | Conditional loss of Pten & activation of KRas | Liver & lung metastasis DTCs bone marrow micrometastasis |
| LPB-Tag(12T-10 subline, LADY) | Conditional activation of large T antigen | Liver, lymph node and lung metastasis Bone micrometastasis |
| Hoxb13-MYC/Hoxb13-Cre/PtenL/L | Conditional MYC overexpression and Pten knockout | Liver, lung and rare thoracic bone metastasis |
Our Advantages
Our company is committed to providing customized one-stop services to accelerate your project development. With professional knowledge, we are committed to providing you with reliable experimental solutions, efficiently providing you with round-the-clock development services to ensure that your development is of low cost and confidentiality.
Qualified Experiment
Timely Delivery
Cost-Effective Services
Highly Confidential
Alfa Cytology is committed to driving prostate cancer research forward through our comprehensive preclinical solutions. Our mission is to advance prostate cancer therapy by providing one-stop modulator development services of prostate cancer growth in bone microenvironments. If you are interested in our services, please don't hesitate to contact us for further information and pricing details.
Reference
- Kang, J., et al. Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer. Cancer letters. 2022, 530: 156-169.
For research use only.